News Releases
-
Ryvu Therapeutics’ Global Licensee Menarini to Expand Development of MEN1703 (SEL24) with a New Study in Advanced Diffuse Large B-Cell Lymphoma (DLBCL) -
Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update -
Ryvu Therapeutics to Participate in the 31st Congress of the Polish Society of Hematology and Transfusion Medicine
What we do
We challenge current treatment paradigms
At Ryvu, we develop therapeutics that address clinical limitations of current treatments in oncology.
Our pipeline includes candidates with differentiated properties from kinase, synthetic lethality, and immuno-oncology programs.
Investor Relations
Ryvu Therapeutics (Selvita Oncology) was founded in 2007. Since 2014, the company has been listed on Warsaw Stock Exchange under the ticker RVU.
Ryvu Therapeutics is organized for highly efficient R&D driven by breakthrough science, aiming to realize full value potential for its shareholders, partners and employees.
See More
65.80 PLN
+0.61%
RVU • 22/09/2023 17:01 • Warsaw Stock Exchange